S9701 Paclitaxel in Treating Patients With Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Remission
Status:
Completed
Trial end date:
2012-11-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing
so they stop growing or die. It is not yet known whether giving paclitaxel for a shorter
period of time is as effective as a standard course of treatment for advanced ovarian cancer.
PURPOSE: Randomized phase III trial to compare the effectiveness of paclitaxel given for 3
months with that of paclitaxel given for 12 months in treating patients who have stage III or
stage IV ovarian, fallopian tube, or primary peritoneal cancer.